2. Search Result
Search Result
Results for "

The K4 peptide

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

7

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16993
    OICR-9429
    Maximum Cited Publications
    15 Publications Verification

    		 Apoptosis WDR5 Cancer
    OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
    OICR-9429
  • HY-12583
    A-366
    5+ Cited Publications

    		 Histone Methyltransferase Epigenetic Reader Domain Cancer
    A-366, a chemical probe, is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC50=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (Ki=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families .
    A-366
  • HY-403538
    iZMYND8-34

    		Zinc Finger Protein Cancer
    iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development .
    iZMYND8-34
  • HY-P5600
    The K4 peptide

    		Bacterial Infection
    The K4 peptide is an antimicrobial peptide with strong activity against Gram-positive and Gram-negative bacteria, including human pathogenic bacteria, such as Staphylococcus aureus and Marine Vibrio bacteria .
    The K4 peptide
  • HY-125837A
    MS31 trihydrochloride
    3 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MS31 trihydrochloride is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 trihydrochloride potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 trihydrochloride selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 trihydrochloride potently inhibits binding of trimethyllysine-containing peptides to SPIN1, and is not toxic to nontumorigenic cells .
    MS31 trihydrochloride
  • HY-P2255
    H3K4(Me) (1-20)

    		Histone Demethylase Others
    H3K4(Me) (1-20), a histone peptide. H3K4me is an intricately regulated posttranslational modification, which is broadly associated with enhancers and promoters of actively transcribed genomic loci .
    H3K4(Me) (1-20)
  • HY-P11456A
    Lipopeptide CPK4 TFA

    		Liposome Others
    Lipopeptide CPK4 TFA is a Cholesterol (HY-N0322)-modified peptide K4 [(KIAALKE) 3]. Lipopeptide CPK4 TFA is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPK4 TFA triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPK4 TFA can be used for drug delivery research .
    Lipopeptide CPK4 TFA
  • HY-P2257
    H3K4(Me3) (1-20)

    		Histone Demethylase Others
    H3K4(Me3) (1-20) is a histone peptide. Trimethylation of histone H3 on lysine 4 (H3K4 me3) is found in active euchromatin but not in silent heterochromatin .
    H3K4(Me3) (1-20)
  • HY-P11456
    Lipopeptide CPK4

    		Liposome Others
    Lipopeptide CPK4 is a Cholesterol (HY-N0322)-modified peptide K4 [(KIAALKE) 3]. Lipopeptide CPK4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPK4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPK4 can be used for drug delivery research .
    Lipopeptide CPK4
  • HY-125837
    MS31

    		Epigenetic Reader Domain Cancer
    MS31 is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 potently inhibits binding of trimethyllysine-containing peptides to SPIN1. MS31 is not toxic to nontumorigenic cells .
    MS31
  • HY-P10819
    S9-CMC1 TFA

    		Histone Demethylase Apoptosis Cancer
    S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .
    S9-CMC1 TFA
  • HY-183602
    FRC-303

    		DNA/RNA Synthesis Cancer
    FRC-303 is a CHD1 inhibitor with a Kd of 0.14 μM and an IC50 of 0.18 μM. FRC-303 binds to the H3K4me3 binding site of CHD1 tandem chromodomain, forms aromatic cage interactions and extended ligand contacts, acts as a methyl-lysine mimic, and occupies natural peptide ligand-binding regions. FRC-303 can be used for the research of prostate cancer .
    FRC-303

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: